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OBJECTIVE: The goal of this project was to analyze the association between Crohn’s disease, its clinical features, and
the tumor necrosis factor alpha (TNF-a) -308 polymorphism.
METHODS: This is a case-control and cross-sectional study that enrolled 91 patients with Crohn’s disease and 91
controls. Patients with Crohn’s disease were characterized according to the Montreal Classification, along with their
clinical and surgical treatment history. Analysis of the TNF-a -308 polymorphism was performed using a commercial
kit. A stratified analysis was applied using an OR (odds ratio) with a 95% confidence interval. The chi-square and
Fisher’s exact tests were utilized for analysis of the association between the polymorphism and the clinical features
of Crohn’s disease.
RESULTS: The low producer predicted phenotype was present in 76.9% of Crohn’s disease cases and 75.8% of
controls (OR 0.94 [0.45-1.97]). The TNF2 allele and the high producer predicted phenotype were more frequent
among patients with Crohn’s disease penetrating behavior (p=0.004). The TNF2 allele and the high producer
predicted phenotype were also associated with a history of colectomy (p=0.02), and the TNF2 allele was associated
with small bowel resection (p=0.03).
CONCLUSIONS: The TNF-a -308 polymorphism appears to affect the severity of the disease. However, TNF-a -308
polymorphism does not appear to be important for the susceptibility in the development of Crohn’s disease.
KEYWORDS: Crohn’s disease; Inflammatory bowel disease; Tumor necrosis factor alpha; Genetic polymorphism;
Mixed-race.
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INTRODUCTION
Crohn’s disease (CD) is a chronic illness of unknown
etiology. Current studies suggest that a combination of
environmental and genetic factors contribute to its patho-
genesis. The inflammatory process in CD is partially due to
the dysregulation of an immune reaction to gut bacteria.
Monocytes and macrophages in the gastrointestinal tract of
CD patients often secrete high amounts of tumor necrosis
factor alpha (TNF-a), which has an essential role in the
disease activity.
1 Crohn’s disease appears to be more
common among whites than individuals of African des-
cent.
2 Some studies suggest that different racial groups
present different characteristics of CD, which could be due
to unique pathogenetic mechanisms in patients of different
ethnic backgrounds. Overall, there is a slight predominance
of CD in females.
3 Additionally, smoking is a potential risk
factor for development of CD.
4
TNF-a is mainly secreted by cells of the immune system,
including monocytes, macrophages, neutrophils, NK cells,
and T lymphocytes. The TNF-a gene is located on the short
arm of chromosome 6 in the HLA region. Several
polymorphisms in its promoter region have been
described.
5 The most important of these polymorphisms is
aG RA substitution at position -308, where the TNF1 (G)
and TNF2 (A) alleles originate.
6 The GG genotype is
associated with a low TNF-a producing predicted pheno-
type, and the other two genotypes (GA+AA) are associated
with a high TNF-a producing predicted phenotype.
7,8 The
association between the TNF-a -308 polymorphism and the
susceptibility to IBD has been previously evaluated, with
conflicting results.
9,10 A European study found that the
frequency of the TNF2 allele was lower in patients with CD
than in healthy controls.
11 Another study found a lower
frequency of the TNF2 allele in ulcerative colitis patients
compared with controls.
12 However, a Japanese study
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1373observed a fourfold increase in the frequency of the TNF2
allele among patients with ulcerative colitis compared with
controls.
13 Another study detected a similar frequency
of the TNF2 allele between IBD and control patients.
14
Polymorphisms at the -308 site of TNF-a are also associated
with the clinical presentation of CD.
15 A study of European
CD patients detected a connection between the frequency of
the TNF2 allele and fistulizing, steroid-dependent and
colonic disease.
11
The aim of this study was to analyze the association
between the incidence of CD and the TNF-a -308 poly-
morphism and to examine the association between this
polymorphism, severity criteria and the clinical features of
Crohn’s disease, such as age at diagnosis, behavior, and
location of the disease.
MATERIALS AND METHODS
This was a cross-sectional and case-control study. We
evaluated patients from outpatient gastroenterology clinics
at the Professor Edgard Santos University Hospital and at
the Roberto Santos General Hospital in Salvador. Patients
and controls were enrolled between March 2006 and May
2007.
Patients 18 years or older were enrolled if they had an
established diagnosis of CD, according to the criteria of
Lennard-Jones.
16 All included patients were subjected to at
least one small bowel follow-through and one colonoscopy
with biopsy. When a colonoscopy could not be performed
because of a suspected stricture, patients underwent a
radiological evaluation of the colon. In cases with symptoms
of the upper GI tract, the patients were subjected to an
upper endoscopy. The classification of CD was based on the
Montreal criteria,
18 which include age at diagnosis, beha-
vior, and location. Race was evaluated according to the
criteria of Krieger.
19 Patients were considered smokers if
they had smoked seven cigarettes or more per week for at
least one year. Only one patient from each family was
enrolled. The complete clinical history of CD, including
clinical and surgical treatment, was obtained from each
patient.
Controls were individuals 18 or older who were evalu-
ated at the listed clinics during the same period of time.
These patients may have been diagnosed with dyspepsia or
esophageal reflux disease. However, these subjects were
required to not have had peptic ulcers, diarrhea, hemato-
chezia, abdominal pain, fistulae, or a family history of
inflammatory bowel disease. A patient’s family history was
considered positive for IBD if it occurred in a first cousin
or closer relative.
To obtain genomic DNA, 10 milliliters of whole blood
was collected from each patient and stored at -4˚C in EDTA
tubes until DNA extraction was performed. Genomic DNA
was purified with the commercial EZ-DNA Kit (Biological
Industries, Kibbutz Beit Haemek, Israel), according to the
manufacturer’s instructions. The TNF-a -308 polymorph-
ism was genotyped with the Cytokine Genotyping Tray
Kit (One Lambda, Canoga Park, CA) according to the
manufacturer’s instructions. The results were interpreted
using maps of the genotyping plates supplied by the
manufacturer.
Sample size was calculated to detect an odds ratio of 2,
considering a frequency of 18% for the TNF2 allele among
controls and a frequency of 36% among cases. The study
was designed to have a power of 80%, with a 5% probability
of an alpha standard error. Using these parameters, it was
determined that each group should contain 91 individuals.
To analyze the results, databases were generated and
analyzed with the SPSS software, version 11.0, and Epi Info,
version 6.04. The study groups were evaluated to determine
whether the TNF alleles were in Hardy-Weinberg
Equilibrium. The main independent variable was carrying
the TNF2 allele, which corresponds with a high TNF-a
producing predicted phenotype. The dependent variable
was the diagnosis of CD. A 262 table was constructed with
the main independent and the dependent variable to ob-
tain odds ratios (OR) and 95% confidence intervals. The
co-variables of interest were gender, racial group (evaluated
as whites or African descent), and smoking (evaluated as
the presence or absence of a smoking history). To analyze
effects of confounding factors and modifiers on the main
association, we performed a stratified analysis using
estimated ORs with 95% confidence intervals, Mantel-
Haenszel adjusted ORs and the Mantel-Haenszel chi-square
test. The co-variables were also evaluated for the possibility
of confounding effects by verifying the difference between
crude OR and Mantel-Haenszel adjusted OR. The chi-square
test or Fisher’s test was used to examine the associations
between the presence of the TNF2 allele and the CD
characteristics. The differences were considered statistically
significant when the probability of the standard error was
,0.05.
Informed written consent was obtained from all subjects.
The study protocol conformed to the ethical guidelines of
the 1975 Declaration of Helsinki and was approved by the
Hospital Ethics Committee.
RESULTS
In total, 91 patients with CD and 91 control patients were
enrolled in the study. Of these 182 patients, 64 cases and 62
controls were from the Professor Edgard Santos University
Hospital, while 27 cases and 29 controls were from the
Roberto Santos General Hospital. The control group
comprised 81 patients with gastroesophageal reflux disease
and 10 patients with functional dyspepsia.
The genotype frequencies of both cases and controls were
found to be in Hardy-Weinberg equilibrium. The mean age
of patients with CD was 38.0¡12.8 years, and that of
controls was 50.3¡13.6 years. Levene’s test was used to
evaluate the homogeneity of variances, and they were
determined to be equal. The difference between the mean
age of cases and controls was statistically significant
(p,0.001).
Three individuals with CD were of Jewish ancestry.
Otherwise, the distribution of racial groups was similar
between cases and controls. Only two patients with CD had
a family history of IBD.
The distribution of the allelic and genotypic frequencies,
along with the predicted phenotypes, for the -308 G/A
polymorphism in the TNF-a promoter region for both
patients with CD and controls is shown in Table 1. The
crude OR and its respective 95% confidence interval for the
presence of the A allele and CD were 1.09 [0.58–2.05], while
the OR for displaying the high producing predicted
phenotype and CD was 0.94 [0.45–1.97]. A positive asso-
ciation was observed between whites (1.25 [0.45–3.50]),
male gender (1.91 [0.98–3.76]) and Crohn’s disease, and a
TNF-a -308 polymorphism
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history (0.67 [0.32–1.37]) and Crohn’s disease. However,
these results were not statistically significant.
Table 2 summarizes the results of the crude ORs with
their respective 95% confidence intervals for displaying the
high producing predicted phenotype and CD and the
stratified analysis for gender, racial group, and smoking.
The results of the Mantel-Haenszel adjusted OR are also
listed in Table 2. Notably, the adjusted OR did not differ
from the crude OR for any of the variables.
The mean time from the onset of initial symptoms to the
establishment of a CD diagnosis was 40.2¡59.2 months
(range 1–324 months), and the median time was 34 months.
The mean age at diagnosis was 32.3¡12.5 years. The
median age at diagnosis was 33 years old, with a range
from 5 to 63 years old. The mean time since CD diagnosis
was 68.8¡66.2 months.
The CD description, according to the Montreal classifica-
tion, is outlined in Table 3. The disease behavior was
defined in 90 patients, and location was identified in 82
patients. In 81 patients, it was possible to classify both
location and behavior. Most patients were diagnosed
between 17 and 40 years old and displayed non-stricturing,
non-penetrating behavior, and an ileocolic location.
A history of perianal fistula was detected in 45.1% (41/91)
of the patients, and a rectovaginal fistula occurred in 5.6%
(3/54) of women. Two patients (3.3%) had an enterocuta-
neous fistula.
The alleles, genotypes, and predicted phenotype frequen-
cies were not associated with age at diagnosis or location
(data not shown).
Patients with penetrating behavior showed a greater
frequency of the high producing phenotype and of the A
allele. Specifically, they were mainly of the AA genotype.
This difference was statistically significant. A complete
description of the frequencies of the alleles, genotypes and
predicted phenotypes according to CD behavior is shown in
Table 4. There was no association between perianal disease
and the TNF-a -308 polymorphism.
The analysis of the severity criteria showed associations
between the TNF2 allele, colectomy (p=0.04) and small
bowel resection (p=0.03). Furthermore, the high producing
predicted phenotype was associated with colectomy
(p=0.02) (Table 5).
DISCUSSION
Recent advances in studies of genetic polymorphisms and
CD are evident, in that the trend for the molecular
classification of this disease is based on studies of genes
associated with particular clinical phenotypes. For example,
the influence of HLA regions appears to be more important
in determining colonic and/or perianal disease, while
mutations in NOD2/CARD15 seem to establish ileal disease
in people diagnosed at a younger age.
20 The first study from
Brazil evaluating genetic polymorphisms in IBD patients
Table 1 - Distribution of alleles, genotypes and predicted
phenotype frequencies of the TNF-a -308 polymorphism
in controls and CD patients.
Cases Controls
Allele n=182 n=182
G, n (%) 155 (85.2) 157 (82.3)
A, n (%) 27 (14.8) 25 (13.7)
Genotype n=91 n=91
GG, n (%) 70 (76.9) 69 (75.8)
GA, n (%) 15 (16.5) 19 (20.9)
AA, n (%) 6 (6.6) 3 (3.3)
Predicted Phenotype n=91 n=91
Low Producer, n (%) 70 (76.9) 69 (75.8)
High Producer, n (%) 21 (23.1) 22 (24.2)
Table 2 - Stratified analysis of association between TNF-a high producing predicted phenotypes and Crohn’s disease
with regard to gender, racial group and smoking.
Variable
Case
n (%)
Control
n (%)
ORS {
[95% CI]
OR A {
[95% CI] p-value *
Gender
Female
Male
54 (59.3)
37 (40.7)
67 (73.6)
24 (26.4)
1.60 [0.63–4.06]
0.32 [0.08–1.24]
0.93 [0.44–1.96] NS
Racial Group
African descent
Whites
80 (87.9)
11 (12.1)
82 (90.1)
9 (9.9)
0.84 [0.38–1.86]
2.0 [0.19–23.4]
0.93 [0.44–1.96] NS
Smoking
Yes
No
20 (22)
71 (78)
27 (29.7)
64 (70.3)
2.33 [0.55–10.14]
0.67 [0.27–1.66]
0.98 [0.46–2.05] NS
Note: Crude odds ratio (OR) for having high producing predicted phenotype and CD=0.94 [0.45–1.97].
{stratified OR.
{adjusted OR.
*Mantel-Haenszel chi-square to test equality of the OR in strata. NS, not statistically significant.
Table 3 - Montreal classification for Crohn’s disease.
Montreal Classification n n
Total
n (%)
Age at diagnosis, n=91
A1 (#16) 12 (13.2)
A2 (17 - 40) 55 (60.4)
A3 (.40) 24 (26.4)
Behavior, n=90
B1 – Non-stricturing, non-penetrating 31 B1+p 31 62 (68.9)
B2 – Stricturing 12 B2+p 1 13 (14.4)
B3 – Penetrating 7 B2+p 8 15 (16.7)
Location n=82
L1 – Terminal ileum 17 L1+L4 _ 17 (20.7)
L2 – Colon 21 L2+L4 _ 21 (25.6)
L3 – Ileocolic 36 L3+L4 7 43 (52.4)
L4 – Upper gastrointestinal 1 1 (1.3)
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does not influence the disease phenotype.
21
TNF-a is a key cytokine in the inflammatory response of
CD and appears to be important in the digestive and
systemic manifestations of the disease. Research on the
polymorphism at position -308 in the promoter region of the
TNF-a gene has demonstrated its importance with regard to
the clinical presentation of CD. Vatay et al.
22 found that
carriers of the TNF2 allele had higher C-reactive protein
levels in the active phase of the disease compared with the
inactive phase. In a study by Gonza ´lez et al.,
15 50 patients
with the penetrating form of CD were evaluated, and the
authors detected an association between the presence of the
A allele and increased serum levels of TNF-a, interleukin 1ß
and proteins of the acute phase. A more intense inflamma-
tory response occurred in GA individuals compared with
GG individuals, along with a higher frequency of arthritis.
Their study included no AA patients.
In an analysis stratified by gender, racial group, and
smoker/non-smoker variables in the current study, none of
these factors were found to modify the effect or confound
the association between the studied polymorphism and CD.
This result reinforces the possibility that this polymorphism
does not have relevance as a risk factor for CD in the studied
population, and it is also in agreement with previous
studies performed in other populations.
15,23 In agreement
with our findings, another study of Brazilian IBD patients
showed no association between this polymorphism and
susceptibility to CD or UC.
24 Although our study was
conducted in another state, those results are still comparable
with ours because a multicentric study evaluating genetic
ancestry in the Brazilian population showed a perfect
genetic admixture from Portuguese, Amerindian and
African genetic ancestries in all states studied, regardless
of the different skin colors of the individuals.
25
Some considerations are relevant in studies that evaluate
the association of genotype and phenotype using a case-
control design. Saito et al. demonstrated the necessity for a
plausible biological rationale when studying cytokine poly-
morphisms. It is not justifiable to examine polymorphisms
only because of their availability, without any suggestion for
a possible association between the studied cytokine and the
pathogenesis of the disease.
26 This study aimed to evaluate
the TNF-a polymorphism, as this cytokine is involved in the
pathogenesis of CD. In addition, it is important to include a
detailed characterization of the control group, which may
sometimes not be comparable with the disease group.
27 To
better match our groups, we only included control subjects
who were treated at the same centers where the study
patients were evaluated and managed.
Individuals under 40 years old at diagnosis presented
with a lower frequency of the high producing predicted
phenotype. It is possible that the TNF-a gene contributes
more to the inflammatory response in older individuals.
Table 4 - Frequencies of the alleles, genotypes and predicted phenotypes for the TNF-a -308 polymorphism according to
CD behavior.
Variable
B1+p
(Non-stricturing non-
penetrating
+perianal) p-value*
B2+p
(Stricturing
+perianal) p-value*
B3+p
(Penetrating
+perianal) p-value*
Alleles n=124 0.003 n=26 NS n=30 0.004**
G, n (%) 112(90.3) 21 (80.8) 20 (66.7)
A, n (%) 12(9.7) 5(19.2) 10(33.3)
Genotypes n=62 n=13 n=15
GG, n (%) 52 (83.9) 9 (69.2) 8 (53.3)
GA, n (%) 8(12.9) 3 (23.1) 4 (26.7)
AA, n (%) 2(3.2) 1 (7.7) 3 (20.0)
Predicted Phenotypes n=62 0.02 n=13 NS n=15 0.02
Low Producer,
n (%)
52 (83.8) 9 (69.2) 8 (53.3)
High Producer,
n (%)
10 (16.2) 4 (30.8) 7 (46.7)
Number of alleles=180; number of patients=90.
*Comparison with the other behaviors. ** Fisher’s exact test.
Table 5 - Frequencies of the alleles and predicted phenotypes for the TNF-a -308 polymorphism according to severity
criteria.
Allele TNF-a predicted phenotype
Severity Criteria
A
n (%)
G
n (%) p-value
High producer
n (%)
Low producer
n (%) p-value
Immunosuppressive treatment 10 (37.0) 60 (38.7) NS 8 (30.1) 27 (38.6) NS
Steroid treatment 19 (70.4) 101 (65.2) NS 15 (71.4) 45 (64.3) NS
Fistula surgery 8 (29.6) 24 (15.5) NS 5 (23.8) 11 (15.7) NS
Colectomy 10 (37.0) 30 (19.4) 0.04 9 (42.9) 11 (15.7) 0.02
Small bowel resection 5 (18.5) 13 (8.4) 0.03* 5 (31.3) 4 (5.7) NS
Hospitalization in the last year { 8 (29.6) 48 (31.4) NS 6 (28.6) 22 (31.9) N
{90 patients, with 27 A alleles, 153 G alleles, 21 high producers and 69 low producers.
*Fisher’s exact test. NS, not statistically significant.
TNF-a -308 polymorphism
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the occurrence of the disease in the youngest individuals.
20
In another study, an association was detected between the
penetrating form of CD and a high TNF-a producing
predicted phenotype.
11 We obtained similar results, show-
ing that the frequency of a high producing predicted
phenotype was greater among individuals with the pene-
trating behavior and that this difference was statistically
significant. Reinforcing this finding, the non-stricturing,
non-penetrating behavior was associated with the low
producing predicted phenotype. Furthermore, the TNF2
allele was associated with the presence of colectomy and
small bowel resection, both of which are associated with
more severe disease. Another study of Brazilian IBD
patients (43 CD patients and 42 UC patients) found no
association between disease phenotype and this polymorph-
ism, but the authors did not report the classification applied,
which prevents a valid comparison with our results.
24
The uniform description of this complex disease may
contribute to the recognition of the real mechanisms
involved in its pathogenesis. We postulate that the lack of
a single classification could be the reason for the absence of
an association between the studied polymorphism and the
severity of CD in other studies. It is also possible that this
polymorphism is in linkage disequilibrium with other
genetic markers. A detailed description of the evolution
and treatment of patients with CD in genetic studies would
be useful in understanding many of the currently unclear
pathogenetic mechanisms of CD.
CONCLUSIONS
In conclusion, the TNF-a -308 polymorphism does not
appear to predispose individuals to the development of CD.
This observation is in agreement with research from other
centers. However, this polymorphism might affect the
behavior of CD. Additionally, the TNF2 allele was asso-
ciated with prior colectomy and small bowel resection,
reinforcing the notion that the TNF-a -308 polymorphism
might affect the severity of CD.
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